181 related articles for article (PubMed ID: 38240765)
1. Efficacy and safety of infliximab in the treatment of Kawasaki disease: A systematic review and meta-analysis.
Wang L; He M; Wang W; Li S; Zhao G
Eur J Pediatr; 2024 Apr; 183(4):1765-1776. PubMed ID: 38240765
[TBL] [Abstract][Full Text] [Related]
2. Intravenous immunoglobulin for the treatment of Kawasaki disease.
Broderick C; Kobayashi S; Suto M; Ito S; Kobayashi T
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD014884. PubMed ID: 36695415
[TBL] [Abstract][Full Text] [Related]
3. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
Jone PN; Anderson MS; Mulvahill MJ; Heizer H; Glodé MP; Dominguez SR
Pediatr Infect Dis J; 2018 Oct; 37(10):976-980. PubMed ID: 29461447
[TBL] [Abstract][Full Text] [Related]
4. Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a meta-analysis.
Li X; Tang Y; Ding Y; Chen Y; Hou M; Sun L; Qian G; Qin L; Lv H
Eur J Pharmacol; 2021 May; 899():173985. PubMed ID: 33652059
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.
Lei WT; Chang LS; Zeng BY; Tu YK; Uehara R; Matsuoka YJ; Su KP; Lee PC; Cavalcante JL; Stubbs B; Lin PY; Wu YC; Hsu CW; Chen TY; Chen YW; Yeh PY; Sun CK; Tseng PT; Kao YH
EBioMedicine; 2022 Apr; 78():103946. PubMed ID: 35306339
[TBL] [Abstract][Full Text] [Related]
6. Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease.
Chan H; Chi H; You H; Wang M; Zhang G; Yang H; Li Q
BMC Pediatr; 2019 May; 19(1):158. PubMed ID: 31101091
[TBL] [Abstract][Full Text] [Related]
7. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
Burns JC; Roberts SC; Tremoulet AH; He F; Printz BF; Ashouri N; Jain SS; Michalik DE; Sharma K; Truong DT; Wood JB; Kim KK; Jain S;
Lancet Child Adolesc Health; 2021 Dec; 5(12):852-861. PubMed ID: 34715057
[TBL] [Abstract][Full Text] [Related]
8. TNF-α blockers for the treatment of Kawasaki disease in children.
Yamaji N; da Silva Lopes K; Shoda T; Ishitsuka K; Kobayashi T; Ota E; Mori R
Cochrane Database Syst Rev; 2019 Aug; 8(8):CD012448. PubMed ID: 31425625
[TBL] [Abstract][Full Text] [Related]
9. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease.
Roberts SC; Jain S; Tremoulet AH; Kim KK; Burns JC; ; Anand V; Anderson M; Ang J; Ansusinha E; Arditi M; Ashouri N; Bartlett A; Chatterjee A; DeBiasi R; Dekker C; DeZure C; Didion L; Dominguez S; El Feghaly R; Erdem G; Halasa N; Harahsheh A; Jackson MA; Jaggi P; Jain S; Jone PN; Kaushik N; Kurio G; Lillian A; Lloyd D; Manaloor J; McNelis A; Michalik DE; Newburger J; Newcomer C; Perkins T; Portman M; Romero J; Ronis T; Rowley A; Schneider K; Schuster J; Tejtel SKS; Sharma K; Simonsen K; Szmuszkovicz J; Truong D; Wood J; Yeh S
Contemp Clin Trials; 2019 Apr; 79():98-103. PubMed ID: 30840903
[TBL] [Abstract][Full Text] [Related]
10. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC
Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997
[TBL] [Abstract][Full Text] [Related]
11. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.
Burns JC; Best BM; Mejias A; Mahony L; Fixler DE; Jafri HS; Melish ME; Jackson MA; Asmar BI; Lang DJ; Connor JD; Capparelli EV; Keen ML; Mamun K; Keenan GF; Ramilo O
J Pediatr; 2008 Dec; 153(6):833-8. PubMed ID: 18672254
[TBL] [Abstract][Full Text] [Related]
12. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.
Han CL; Zhao SL
Med Sci Monit; 2018 Oct; 24():7264-7270. PubMed ID: 30307902
[TBL] [Abstract][Full Text] [Related]
13. Current knowledge of TNF-α monoclonal antibody infliximab in treating Kawasaki disease: a comprehensive review.
Chen J; Liao J; Xiang L; Zhang S; Yan Y
Front Immunol; 2023; 14():1237670. PubMed ID: 37936712
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.
Mori M; Imagawa T; Hara R; Kikuchi M; Hara T; Nozawa T; Miyamae T; Yokota S
J Rheumatol; 2012 Apr; 39(4):864-7. PubMed ID: 22337241
[TBL] [Abstract][Full Text] [Related]
15. Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin.
Burns JC; Song Y; Bujold M; Shimizu C; Kanegaye JT; Tremoulet AH; Franco A
Clin Exp Immunol; 2013 Dec; 174(3):337-44. PubMed ID: 23901839
[TBL] [Abstract][Full Text] [Related]
16. Infliximab as a second-line therapy for children with refractory Kawasaki disease: A systematic review and meta-analysis of randomized controlled trials.
Kabbaha S; Milano A; Aldeyab MA; Thorlund K
Br J Clin Pharmacol; 2023 Jan; 89(1):49-60. PubMed ID: 36169097
[TBL] [Abstract][Full Text] [Related]
17. Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review.
Crayne CB; Mitchell C; Beukelman T
Pediatr Rheumatol Online J; 2019 Nov; 17(1):77. PubMed ID: 31775898
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy and safety of glucocorticoids in addition to intravenous immunoglobulin in the initial treatment of Kawasaki disease: a meta-analysis of randomized trials].
Hu JW; Zhou ZS; Yang L; Zheng CN; Wang KD
Zhonghua Yi Xue Za Zhi; 2011 May; 91(18):1259-64. PubMed ID: 21756798
[TBL] [Abstract][Full Text] [Related]
19. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial.
Mori M; Hara T; Kikuchi M; Shimizu H; Miyamoto T; Iwashima S; Oonishi T; Hashimoto K; Kobayashi N; Waki K; Suzuki Y; Otsubo Y; Yamada H; Ishikawa C; Kato T; Fuse S
Sci Rep; 2018 Jan; 8(1):1994. PubMed ID: 29386515
[TBL] [Abstract][Full Text] [Related]
20. Infliximab for intensification of primary therapy for patients with Kawasaki disease and coronary artery aneurysms at diagnosis.
Miyata K; Bainto EV; Sun X; Jain S; Dummer KB; Burns JC; Tremoulet AH
Arch Dis Child; 2023 Oct; 108(10):833-838. PubMed ID: 37258054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]